European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology and Gynecological Oncology, Charité Comprehensive Cancer Center (CCCC), Charité-University Medicine of Berlin, Campus Virchow Klinikum, Augustenberger Platz 1, 13353 Berlin, Germany; Department of Obstetrics and Gynecology, Demiroglu Bilim University School of Medicine, Sisli Florence Nightingale Hospital, 34394 Istanbul, Turkey.
European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology and Gynecological Oncology, Charité Comprehensive Cancer Center (CCCC), Charité-University Medicine of Berlin, Campus Virchow Klinikum, Augustenberger Platz 1, 13353 Berlin, Germany.
Gynecol Oncol. 2019 Sep;154(3):539-546. doi: 10.1016/j.ygyno.2019.06.014. Epub 2019 Jun 21.
Low-grade epithelial ovarian cancers (EOC), constitute the minority among all epithelial cancers. Our study objective was to focus on low-grade recurrent EOC and compare the survival with high-grade disease, as well as in regard to "platinum-sensitive" and "-resistant" recurrences according to platinum-free interval.
This is an exploratory analysis within the North-Eastern German Society of Gynecological Oncology (NOGGO) database including five randomized phase II/III trials comparing different chemotherapy regimens in recurrent EOC. We conducted survival analyses and cox-proportional regression models.
Out of 1050 patients having the first recurrence, 42 (4%) patients had low-grade and 1008 (96%) patients had high-grade disease. In the subgroup of platinum-sensitive recurrences, progression-free survival (PFS) (8.7 m vs 9.7 m, p = 0.7) and overall survival (OS) (23.9 m vs 24.8 m, p = 0.9) did not differ between low-grade and high-grade diseases. In platinum-resistant recurrences, patients with low-grade ovarian cancer had significantly better PFS (7.6 m vs 3.6 m, p = 0.03) and OS (41.9 m vs 9.5 m p = 0.002) in comparison to those with high-grade cancer. At low-grade EOC, there were no significant PFS (p = 0.91) and OS (p = 0.25) differences between platinum-sensitive and -resistant recurrences. Patients with low-grade non-serous histology had lower PFS with compared to those with low-grade serous histology (p = 0.004). At cox regression analysis presence of ascites and residual disease after secondary cytoreductive surgery were independently associated with poor PFS within low-grade recurrent EOC.
Our study indicates, platinum-free interval does not have any prognostic significance at recurrent low-grade EOC and non-serous histology is associated with poorer outcome in recurrence. Secondary surgical cytoreduction to no-gross residual disease and ascites are independently associated with disease progression.
低级别上皮性卵巢癌(EOC)构成所有上皮性癌症中的少数。我们的研究目的是关注低级别复发性 EOC,并比较其与高级别疾病的生存率,以及根据无铂间期比较“铂敏感”和“铂耐药”复发。
这是在包括五项比较复发性 EOC 中不同化疗方案的东北德国妇科肿瘤学会(NOGGO)数据库中的一项探索性分析。我们进行了生存分析和 Cox 比例风险回归模型分析。
在 1050 例首次复发的患者中,42 例(4%)患者为低级别,1008 例(96%)患者为高级别疾病。在铂敏感复发亚组中,无进展生存期(PFS)(8.7m 与 9.7m,p=0.7)和总生存期(OS)(23.9m 与 24.8m,p=0.9)在低级别和高级别疾病之间没有差异。在铂耐药复发中,低级别卵巢癌患者的 PFS(7.6m 与 3.6m,p=0.03)和 OS(41.9m 与 9.5m,p=0.002)明显优于高级别癌症患者。在低级别 EOC 中,铂敏感和耐药复发之间 PFS(p=0.91)和 OS(p=0.25)无显著差异。与低级别浆液性组织学相比,低级别非浆液性组织学患者的 PFS 较低(p=0.004)。在 Cox 回归分析中,腹水和二次细胞减瘤术后残留疾病的存在与低级别复发性 EOC 的不良 PFS 独立相关。
我们的研究表明,无铂间期在复发性低级别 EOC 中没有任何预后意义,非浆液性组织学与复发时的不良结局相关。二次手术细胞减瘤至无肉眼残留病灶和腹水与疾病进展独立相关。